Literature DB >> 22691431

HI responses induced by seasonal influenza vaccination are associated with clinical protection and with seroprotection against non-homologous strains.

Willem Luytjes1, Vincent Enouf, Maarten Schipper, Karlijn Gijzen, Wai Ming Liu, Mariken van der Lubben, Adam Meijer, Sylvie van der Werf, Ernst C Soethout.   

Abstract

Vaccination against influenza induces homologous as well as cross-specific hemagglutination inhibiting (HI) responses. Induction of cross-specific HI responses may be essential when the influenza strain does not match the vaccine strain, or even to confer a basic immune response against a pandemic influenza virus. We carried out a clinical study to evaluate the immunological responses after seasonal vaccination in healthy adults 18-60 years of age, receiving the yearly voluntary vaccination during the influenza season 2006/2007. Vaccinees of different age groups were followed for laboratory confirmed influenza (LCI) and homologous HI responses as well as cross-specific HI responses against the seasonal H1N1 strain of 2008 and pandemic H1N1 virus of 2009 (H1N1pdm09) were determined. Homologous HI titers that are generally associated with protection (i.e. seroprotective HI titers ≥40) were found in more than 70% of vaccinees. In contrast, low HI titers before and after vaccination were significantly associated with seasonal LCI. Cross-specific HI titers ≥40 against drifted seasonal H1N1 were found in 69% of vaccinees. Cross-specific HI titers ≥40 against H1N1pdm09 were also significantly induced, especially in the youngest age group. More specifically, cross-specific HI titers ≥40 against H1N1pdm09 were inversely correlated with age. We did not find a correlation between the subtype of influenza which was circulating at the age of birth of the vaccinees and cross-specific HI response against H1N1pdm09. These data indicate that the HI titers before and after vaccination determine the vaccination efficacy. In addition, in healthy adults between 18 and 60 years of age, young adults appear to be best able to mount a cross-protective HI response against H1N1pdm09 or drifted seasonal influenza after seasonal vaccination.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22691431     DOI: 10.1016/j.vaccine.2012.05.060

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  The antibody response to influenza vaccination is not impaired in type 2 diabetics.

Authors:  Patricia A Sheridan; Heather A Paich; Jean Handy; Erik A Karlsson; Stacey Schultz-Cherry; Michael Hudgens; Sam Weir; Terry Noah; Melinda A Beck
Journal:  Vaccine       Date:  2015-06-01       Impact factor: 3.641

2.  Seasonal Influenza Vaccination of Children Induces Humoral and Cell-Mediated Immunity Beyond the Current Season: Cross-reactivity With Past and Future Strains.

Authors:  Adrian J Reber; Jin Hyang Kim; Laura A Coleman; Sarah M Spencer; Jessie R Chung; Jufu Chen; Paul Gargiullo; Maria E Sundaram; Edward A Belongia; David K Shay; Jacqueline M Katz; Suryaprakash Sambhara
Journal:  J Infect Dis       Date:  2016-08-28       Impact factor: 5.226

3.  Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.

Authors:  Christof David Vinnemeier; Johanna Fischer-Herr; Seetha Meyer; Katja Liebig; Wiebke Theeß; Gerd-Dieter Burchard; Jakob P Cramer
Journal:  Hum Vaccin Immunother       Date:  2013-11-15       Impact factor: 3.452

4.  Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons.

Authors:  Huong Q McLean; Mark G Thompson; Maria E Sundaram; Jennifer K Meece; David L McClure; Thomas C Friedrich; Edward A Belongia
Journal:  Clin Infect Dis       Date:  2014-09-29       Impact factor: 9.079

5.  Negative Effect of Age, but Not of Latent Cytomegalovirus Infection on the Antibody Response to a Novel Influenza Vaccine Strain in Healthy Adults.

Authors:  Sara P H van den Berg; Albert Wong; Marion Hendriks; Ronald H J Jacobi; Debbie van Baarle; Josine van Beek
Journal:  Front Immunol       Date:  2018-01-29       Impact factor: 7.561

6.  Influenza vaccination in the elderly: 25 years follow-up of a randomized controlled trial. No impact on long-term mortality.

Authors:  Ruud Andreas Fritz Verhees; Carel Thijs; Ton Ambergen; Geert Jan Dinant; Johannes Andreas Knottnerus
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

7.  Immunogenicity of Influenza Vaccines: Evidence for Differential Effect of Secondary Vaccination on Humoral and Cellular Immunity.

Authors:  Sietske K Rosendahl Huber; Marion Hendriks; Ronald H J Jacobi; Jan van de Kassteele; Jolanda C Mandersloot-Oskam; Renée A J van Boxtel; Anne M J Wensing; Nynke Y Rots; Willem Luytjes; Josine van Beek
Journal:  Front Immunol       Date:  2019-01-29       Impact factor: 7.561

8.  Impact of Immune Priming, Vaccination, and Infection on Influenza A(H3N2) Antibody Landscapes in Children.

Authors:  Michael Hinojosa; Samuel S Shepard; Jessie R Chung; Jennifer P King; Huong Q McLean; Brendan Flannery; Edward A Belongia; Min Z Levine
Journal:  J Infect Dis       Date:  2021-08-02       Impact factor: 5.226

9.  An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.

Authors:  Natalie E Stevens; Cara K Fraser; Mohammed Alsharifi; Michael P Brown; Kerrilyn R Diener; John D Hayball
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

10.  Metformin-induced suppression of IFN-α via mTORC1 signalling following seasonal vaccination is associated with impaired antibody responses in type 2 diabetes.

Authors:  Wipawee Saenwongsa; Arnone Nithichanon; Malinee Chittaganpitch; Kampaew Buayai; Chidchamai Kewcharoenwong; Boonyarat Thumrongwilainet; Patcharavadee Butta; Tanapat Palaga; Yoshimasa Takahashi; Manabu Ato; Ganjana Lertmemongkolchai
Journal:  Sci Rep       Date:  2020-02-24       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.